Clinical and immunological characteristics of autoimmune addison disease : A nationwide swedish multicenter study
(2017) In Journal of Clinical Endocrinology and Metabolism 102(2). p.379-389- Abstract
Context: Studies of the clinical and immunological features of autoimmune Addison disease (AAD) are needed to understand the disease burden and increased mortality. Objective: To provide upgraded data on autoimmune comorbidities, replacement therapy, autoantibody profiles, and cardiovascular risk factors. Design, Setting, and Participants: A cross-sectional, population-based study that included 660 AAD patients from the Swedish Addison Registry (2008-2014). When analyzing the cardiovascular risk factors, 3594 individuals from the population-based survey in Northern Sweden, MONICA (monitoring of trends and determinants of cardiovascular disease), served as controls. Main Outcome Measures: The endpoints were the prevalence of autoimmune... (More)
Context: Studies of the clinical and immunological features of autoimmune Addison disease (AAD) are needed to understand the disease burden and increased mortality. Objective: To provide upgraded data on autoimmune comorbidities, replacement therapy, autoantibody profiles, and cardiovascular risk factors. Design, Setting, and Participants: A cross-sectional, population-based study that included 660 AAD patients from the Swedish Addison Registry (2008-2014). When analyzing the cardiovascular risk factors, 3594 individuals from the population-based survey in Northern Sweden, MONICA (monitoring of trends and determinants of cardiovascular disease), served as controls. Main Outcome Measures: The endpoints were the prevalence of autoimmune comorbidities and cardiovascular risk factors. Autoantibodies against 13 autoantigens were determined. Results: The proportion of 21-hydroxylase autoantibody-positive patients was 83%, and 62% of patients had ≥1 associated autoimmune diseases, more frequently coexisting in females (P < 0.0001). AAD patients had a lower body mass index (P < 0.0001) and prevalence of hypertension (P = 0.027) compared with controls. Conventional hydrocortisone tablets were used by 89% of the patients, with a mean dose of 28.1 ± 8.5 mg/d. The mean hydrocortisone equivalent dose normalized to the body surface was 14.8±4.4 mg/m2/d. A greater hydrocortisone equivalent dose was associated with a greater incidence of hypertension (P = 0.046). Conclusions: Careful monitoring of AAD patients is warranted to detect associated autoimmune diseases. Contemporary Swedish AAD patients did not have an increased prevalence of overweight, hypertension, type 2 diabetes mellitus, or hyperlipidemia. However, high glucocorticoid replacement doses could be a risk factor for hypertension.
(Less)
- author
- organization
- publishing date
- 2017-02-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Endocrinology and Metabolism
- volume
- 102
- issue
- 2
- pages
- 11 pages
- publisher
- Oxford University Press
- external identifiers
-
- scopus:85012097745
- pmid:27870550
- wos:000397240900009
- ISSN
- 0021-972X
- DOI
- 10.1210/jc.2016-2522
- language
- English
- LU publication?
- yes
- id
- 0a2e5f69-3758-4f96-9ba7-d5ea41844677
- date added to LUP
- 2017-03-03 07:44:57
- date last changed
- 2024-12-24 08:52:16
@article{0a2e5f69-3758-4f96-9ba7-d5ea41844677,
abstract = {{<p>Context: Studies of the clinical and immunological features of autoimmune Addison disease (AAD) are needed to understand the disease burden and increased mortality. Objective: To provide upgraded data on autoimmune comorbidities, replacement therapy, autoantibody profiles, and cardiovascular risk factors. Design, Setting, and Participants: A cross-sectional, population-based study that included 660 AAD patients from the Swedish Addison Registry (2008-2014). When analyzing the cardiovascular risk factors, 3594 individuals from the population-based survey in Northern Sweden, MONICA (monitoring of trends and determinants of cardiovascular disease), served as controls. Main Outcome Measures: The endpoints were the prevalence of autoimmune comorbidities and cardiovascular risk factors. Autoantibodies against 13 autoantigens were determined. Results: The proportion of 21-hydroxylase autoantibody-positive patients was 83%, and 62% of patients had ≥1 associated autoimmune diseases, more frequently coexisting in females (P < 0.0001). AAD patients had a lower body mass index (P < 0.0001) and prevalence of hypertension (P = 0.027) compared with controls. Conventional hydrocortisone tablets were used by 89% of the patients, with a mean dose of 28.1 ± 8.5 mg/d. The mean hydrocortisone equivalent dose normalized to the body surface was 14.8±4.4 mg/m2/d. A greater hydrocortisone equivalent dose was associated with a greater incidence of hypertension (P = 0.046). Conclusions: Careful monitoring of AAD patients is warranted to detect associated autoimmune diseases. Contemporary Swedish AAD patients did not have an increased prevalence of overweight, hypertension, type 2 diabetes mellitus, or hyperlipidemia. However, high glucocorticoid replacement doses could be a risk factor for hypertension.</p>}},
author = {{Dalin, Frida and Eriksson, Gabriel Nordling and Dahlqvist, Per and Hallgren, Asa and Wahlberg, Jeanette and Ekwall, Olov and Soderberg, Stefan and Ronnelid, Johan and Olcen, Per and Winqvist, Ola and Catrina, Sergiu-Bogdan and Kristrom, Berit and Laudius, Maria and Isaksson, Magnus and Stenlid, Maria Halldin and Gustafsson, Jan and Gebre-Medhin, Gennet and Bjornsdottir, Sigridur and Janson, Annika and Akerman, Anna Karin and Aman, Jan and Duchen, Karel and Bergthorsdottir, Ragnhildur and Johannsson, Gudmundur and Lindskog, Emma and Landin-Olsson, Mona and Elfving, Maria and Waldenstrom, Erik and Hulting, Anna Lena and Kampe, Olle and Bensing, Sophie}},
issn = {{0021-972X}},
language = {{eng}},
month = {{02}},
number = {{2}},
pages = {{379--389}},
publisher = {{Oxford University Press}},
series = {{Journal of Clinical Endocrinology and Metabolism}},
title = {{Clinical and immunological characteristics of autoimmune addison disease : A nationwide swedish multicenter study}},
url = {{http://dx.doi.org/10.1210/jc.2016-2522}},
doi = {{10.1210/jc.2016-2522}},
volume = {{102}},
year = {{2017}},
}